[go: up one dir, main page]

US20110071162A1 - Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof - Google Patents

Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof Download PDF

Info

Publication number
US20110071162A1
US20110071162A1 US12/956,892 US95689210A US2011071162A1 US 20110071162 A1 US20110071162 A1 US 20110071162A1 US 95689210 A US95689210 A US 95689210A US 2011071162 A1 US2011071162 A1 US 2011071162A1
Authority
US
United States
Prior art keywords
trifluoromethylphenyl
pyridin
methanone
triazolo
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/956,892
Inventor
Luc Even
Christian Hoornaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to US12/956,892 priority Critical patent/US20110071162A1/en
Publication of US20110071162A1 publication Critical patent/US20110071162A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, to the preparation thereof and to the therapeutic use thereof.
  • the compounds of formula (I) may comprise one or more asymmetric carbon atoms. They may therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, are part of the invention.
  • the compounds of formula (I) may exist in the form of bases or of addition salts with acids. Such addition salts are part of the invention.
  • salts may be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating the compounds of formula (I) are also part of the invention.
  • the compounds of formula (I) may also exist in the form of hydrates or of solvates, i.e. in the form of associations or combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.
  • a first group of compounds is constituted of the compounds for which:
  • protective group Pg is intended to mean a group which makes it possible, on the one hand, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, on the other hand, to regenerate the intact reactive function at the end of synthesis.
  • Examples of protective groups and also methods of protection and deprotection are given in “Protective Groups in Organic Synthesis”, Green et al., 2 nd Edition (John Wiley & Sons, Inc., New York), 1991.
  • leaving group is intended to mean a group that can be readily cleaved from a molecule by breaking a heterolytic bond, with the departure of a pair of electrons. This group can thus be readily replaced with another group during a substitution reaction, for example.
  • Such leaving groups are, for example, halogens or an activated hydroxyl group, such as a methanesulfonate, benzenesulfonate, p-toluenesulfonate, triflate, acetate, etc. Examples of leaving groups and also references for the preparation thereof are given in “Advances in Organic Chemistry”, J. March, 3 rd Edition, Wiley Interscience, 1985, p. 310-316.
  • the compounds of general formula (I) can be prepared according to the process illustrated in scheme 1 which follows.
  • pathway A in a first stage, the compounds of general formula (II), in which X is as defined above, are converted to compounds of general formula (III), in which X and R 1 are as defined above.
  • the conversion is carried out by means of a coupling reaction with a boronic acid or a boronate of respective general formula (IV) or (V), in which R 1 is as defined above, and (OR′′) 2 is a pinacol group, catalyzed by a palladium complex.
  • the compounds of general formula (III), in which X and R 1 are as defined above, are converted to compounds of general formula (VI), in which R 1 , R 2 , X and A are as defined above, by reaction with a carbamoyl chloride of general formula (VII).
  • the reaction is carried out in a solvent such as N,N-dimethylformamide or N-methylpyrrolidone, in the presence of a base such as sodium hydride, potassium tert-butoxide or potassium tert-pentoxide.
  • the compounds of general formula (VI) are converted to compounds of general formula (VIII), in which R 2 , A, R 1 and X are as defined above, by reduction of the nitro group to an amino group.
  • the reaction can be carried out by various methods described in the literature or known to those skilled in the art, for instance hydrogenation in the presence of a catalyst based on palladium, platinum or nickel and variants thereof.
  • the compounds of general formula (VIII) are converted to compounds of general formula (I) by means of a diazotization/ring-closure reaction.
  • the reaction can be carried out using a nitrite, for example sodium nitrite or potassium nitrite in an acidic medium or isoamyl nitrite or tert-butyl nitrite, in solvents such as water or tetrahydrofuran or a mixture thereof.
  • Pathway B of scheme 1 illustrates an alternative method for preparing the compounds of formula (I).
  • the compounds of general formula (II) are converted to compounds of general formula (IX) by reaction with a carbamoyl chloride of general formula (VII) as defined above.
  • the compounds of general formula (IX) are converted to compounds of general formula (VI) by reaction with a boronic acid or a boronate of general formula (IV) or (V), as defined above.
  • the compounds of general formula (VI) are subsequently converted to compounds of general formula (VIII) and then to compounds of general formula (I) as specified above.
  • the compounds of general formulae (II), (IV) and (V) are commercially available.
  • the carbamoyl chlorides of general formula (VII), if they are not commercially available, can be prepared by any method described in the literature or known to those skilled in the art, for example starting from the corresponding amines by reaction with phosgene, diphosgene or triphosgene.
  • the mixture is cooled with an ice bath and 40 ml of a 1M aqueous solution of hydrochloric acid are added dropwise. 40 ml of ethyl acetate are added and the mixture is stirred vigorously for 15 minutes. The resulting mixture is adjusted to basic pH by adding a 1M aqueous solution of sodium hydroxide. The organic phase is separated by settling out and washed with 25 ml of water and 25 ml of a saturated aqueous solution of sodium chloride. The resulting product is dried over sodium sulfate and evaporated to dryness.
  • the product is purified by silica gel chromatography, elution being carried out with an 80:20 then 60:40 mixture of cyclohexane and ethyl acetate. 1.54 g (yield: 62%) of product are obtained in the form of an orange gum.
  • Pathway A alternatively, the 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [6-(4-chlorophenyl)-3-nitropyridin-2-yl]amide can be prepared as follows.
  • the resulting mixture is cooled to ambient temperature and then diluted with 50 ml of dichloromethane and 25 ml of water.
  • the organic phase is separated by settling out and washed with 25 ml of water and 25 ml of a saturated solution of sodium chloride.
  • the resulting product is dried over sodium sulfate and evaporated to dryness.
  • the product is purified by silica gel chromatography, elution being carried out with a 50:50 then 80:20 mixture of dichloromethane and cyclohexane. 0.395 g (yield: 27%) of 6-(4-chlorophenyl)-3-nitropyridin-2-ylamine is obtained in the form of a white powder.
  • This product is used as in stage 1.1 in order to obtain the 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [6-(4-chlorophenyl)-3-nitropyridin-2-yl]amide.
  • Table 1 which follows illustrates the chemical structures and the physical properties of some examples of compounds according to the invention. In this table:
  • the compounds according to the invention surprisingly exhibit an inhibitory effect on the MGL (monoacyl glycerol lipase) enzyme.
  • the MGL enzyme catalyzes the hydrolysis of endogenous derivatives of monoglyceride esters of various fatty acids (FEBS Letters 1998, 429, 152-156) and in particular the hydrolysis of 2-arachidonoylglycerol (2-AG) and of 1(3)-arachidonoylglycerol (1(3)-AG) (J. Biol. Chem. 1987, 272 (48), 27218-27223; Proc. Natl. Acad. Sci. USA 2002, 99 (16), 10819-10824; Biochem. Pharmacol. 2004, 67, 1381-1387; Mol. Pharmacol.
  • the 2-AG and 1(3)-AG derivatives in particular interact with cannabinoid receptors (J. Biol. Chem. 1999, 274 (5), 2794-2801; J. Biol. Chem. 2000, 275 (1), 605-612; British J. Pharmacol. 2001, 134, 664-672).
  • the compounds of the invention block this degradation pathway and increase the tissue levels of these derivatives, and in particular of 2-AG and/or of 1(3)-AG.
  • they can be used in the prevention and treatment of pathological conditions in which 2-AG and/or 1(3)-AG in particular, and/or any other substrate metabolized by the MGL enzyme, is (are) involved (Progress Lipid Research 2006, 45, 405-446).
  • the compounds according to the invention may also additionally have an inhibitory effect on the FAAH (Fatty Acid Amide Hydrolase) enzyme.
  • the FAAH enzyme ( Chemistry and Physics of Lipids (2000), 108, 107-121) catalyzes the hydrolysis of endogenous derivatives of amides and of esters of various fatty acids, such as N-arachidonoylethanolamine (anandamide), N-palmitoylethanolamine, N-oleoylethanolamine or oleamide. These derivatives exercise various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors.
  • the compounds of the invention block this degradation pathway and increase the tissue levels of these endogenous substances.
  • they can be used in the prevention and treatment of pathological conditions in which endogenous cannabinoids and/or any other substrate metabolized by the FAAH enzyme is (are) involved.
  • Tests comprised measuring the activity, in vitro, of the compounds of the invention on the MGL enzyme.
  • the inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis of 2-oleoyl glycerol ([ 3 H] 2-OG) by MGL.
  • the products of hydrolysis of [ 3 H] 2-OG, labeled on the glycerol, are oleic acid and [ 3 H] glycerol, and the source of MGL enzyme is a homogenate of mouse brain from which the cerebellum and the medulla oblongata have been removed.
  • the mouse brains are removed, and stored at ⁇ 80° C.
  • the dilution series of the compounds is prepared from stock solutions at 20 mM in 100% DMSO.
  • the first dilution of this series is prepared in 100% DMSO and then the second is prepared in the enzyme reaction buffer (50 mM phosphate, 0.1% BSA) leading to the preparation of a 10-times concentrated concentration range.
  • the test compounds are preincubated at the selected concentration, for 20 minutes, with the mouse brain homogenate preparation.
  • the final concentration of DMSO in the enzyme reaction does not exceed 0.1%.
  • Assaying of the MGL activity is carried out in a 96-well microplate in a final reaction volume of 100 ⁇ l. Briefly, 75 ⁇ g of proteins, preincubated with the test compounds, are diluted in 50 mM of phosphate buffer containing 0.1% BSA, and incubated, for 20 minutes at ambient temperature, in the presence of 50 ⁇ M of 2-OG containing an amount of [ 3 H] 2-OG of 0.027 ⁇ Ci/well (specific activity of 20 Ci/mmol). The reaction is stopped and the products formed are separated by adding and mixing 100 ⁇ l of chloroform/methanol (1/1).
  • the microplate After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and a 30 ⁇ l aliquot of the aqueous phase containing the [ 3 H] glycerol produced is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).
  • the inhibitory activity with respect to MGL is given by the concentration which inhibits 50% of the activity of MGL.
  • the most active compounds of the invention exhibit an IC 50 (concentration inhibiting 50% of the control enzyme activity of MGL) of between 0.001 and 0.1 ⁇ M.
  • compounds Nos. 3 and 5 showed an IC 50 of 0.002 and 0.007 ⁇ M, respectively.
  • Tests comprised measuring the activity, in vitro, of the compounds of the invention on the FAAH enzyme.
  • the inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis (ethanolamine [1-3H]) of anandamide by FAAH (Life Science (1995), 56, 1999-2005 and Journal of Pharmacology and Experimented Therapeutics (1997), 283, 729-734).
  • the products of hydrolysis of [ 3 H] anandamide, labeled on ethanolamine are arachidonic acid and [ 3 H]ethanolamine, and the source of FAAH enzyme is a homogenate of mouse brain from which the cerebellum and the medulla oblongata have been removed. The mouse brains are removed, and stored at ⁇ 80° C.
  • the dilution series of the compounds is prepared from stock solutions at 20 mM in 100% DMSO.
  • the first dilution of this series is prepared in 100% DMSO, then the second is prepared in the enzyme reaction buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 8), 0.1% BSA) leading to the preparation of a 10-times concentrated concentration range.
  • the test compounds are preincubated at the selected concentration for 20 minutes with the mouse brain homogenate preparation. The final concentration of DMSO in the enzyme reaction does not exceed 0.1%.
  • Assaying of the FAAH activity is carried out in a 96-well microplate in a final reaction volume of 70 ⁇ l. Briefly, 200 ⁇ g of mouse brain homogenate, preincubated with the test compounds, are diluted in 10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 8) containing 0.1% of BSA and incubated, for 20 minutes at ambient temperature, in the presence of 10 ⁇ M of anandamide containing an amount of [ 3 H]-anandamide of 0.01 ⁇ Ci/well (specific activity of 60 Ci/mmol). The reaction is stopped and the products formed are separated by adding and mixing 140 ⁇ l of chloroform/methanol (2/1).
  • the microplate After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and a 30 ⁇ l aliquot of the aqueous phase containing the [ 3 H]ethanolamine produced is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).
  • the most active compounds of the invention exhibit an IC 50 (concentration inhibiting 50% of the control enzyme activity of FAAH) of between 0.001 and 0.1 ⁇ M.
  • compound No. 3 showed an IC 50 of 0.002 ⁇ M.
  • the compounds according to the invention have an inhibitory activity which is selective with respect to MGL or mixed with respect to MGL and FAAH.
  • the compounds according to the invention can therefore be used for the preparation of medicaments, in particular of medicaments which inhibit the MGL enzyme or the MGL and FAAH enzymes.
  • a subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid, or else a hydrate or a solvate of the compound of formula (I).
  • the present invention relates to pharmaceutical compositions comprising, as active ingredient, a compound according to the invention.
  • These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or a solvate of said compound, and also at least one pharmaceutically acceptable excipient.
  • Said excipients are selected, according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
  • compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration the active ingredient of formula (I) above, or a possible salt, solvate or hydrate thereof, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or treatment of the disorders or diseases above.
  • Suitable unit administration forms comprise oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants.
  • oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants.
  • the compounds according to the invention may be used in creams, gels, ointments or lotions.
  • a unit administration form of a compound according to the invention in tablet form may comprise the following components:
  • the present invention also relates to a method for treating the pathological conditions indicated above, which comprises the administration of an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt or hydrate or solvate thereof, to a patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)

Abstract

The disclosure relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I):
Figure US20110071162A1-20110324-C00001
wherein X, A, R1 and R2 are as defined herein. The invention further relates to preparation methods and therapeutic use thereof.

Description

  • This application is a continuation of U.S. application Ser. No. 12/577,777, filed Oct. 13, 2009, now allowed, which is a continuation of International Application No. PCT/FR2008/000536, filed Apr. 16, 2008, which are incorporated herein by reference in their entirety; and claims the benefit of priority of French Patent Application No. 0702808, filed Apr. 18, 2007.
  • The present invention relates to triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, to the preparation thereof and to the therapeutic use thereof.
  • The subject of the present invention is the compounds corresponding to formula (I)
  • Figure US20110071162A1-20110324-C00002
  • in which:
      • A and X are, independently of one another, a nitrogen atom or a CH group,
      • R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from a halogen atom or a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy or halo(C1-C6)alkoxy group,
      • R2 is an aryl group optionally substituted with one or more groups selected from a halogen atom or a methyl, trifluoromethyl, methoxy or trifluoromethoxy group.
  • The compounds of formula (I) may comprise one or more asymmetric carbon atoms. They may therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, are part of the invention.
  • The compounds of formula (I) may exist in the form of bases or of addition salts with acids. Such addition salts are part of the invention.
  • These salts may be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating the compounds of formula (I) are also part of the invention.
  • The compounds of formula (I) may also exist in the form of hydrates or of solvates, i.e. in the form of associations or combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.
  • In the context of the present invention:
      • the term “Ct-z”, where t and z may take the values from 1 to 7, is intended to mean a carbon-based chain or ring that may contain from t to z carbon atoms; for example, C1-3 can characterize a carbon-based chain containing from 1 to 3 carbon atoms;
      • the term “a halogen atom” is intended to mean: a fluorine, a chlorine, a bromine or an iodine;
      • the term “an alkyl group” is intended to mean: a linear or branched, saturated aliphatic group. By way of examples, mention may be made of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, etc., groups;
      • the term “a haloalkyl group” is intended to mean: an alkyl group in which one or more hydrogen atoms has (have) been substituted with a halogen (such as for example fluorine) atom;
      • the term “an alkoxy group” is intended to mean: an —O-alkyl radical where the alkyl group is as defined above;
      • the term “a haloalkoxy group” is intended to mean: an alkoxy radical in which one or more hydrogen atoms has (have) been substituted with a halogen atom;
      • the term “an aryl group” is intended to mean: a cyclic aromatic group containing between 5 and 14 carbon atoms. By way of examples of aryl groups, mention may be made of phenyl or naphthyl;
      • the term “a heteroaryl group” is intended to mean: an aromatic heterocyclic group comprising either 5 or 6 carbon atoms and comprising from 1 to 4 heteroatoms, such as nitrogen, oxygen or sulfur. By way of examples of heteroaryl groups, mention may be made of pyrrole, furan, thiophene, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyrimidine, pyrazine, pyridazine or triazine.
  • In the various groups as defined below, the groups A, X, R1 and R2, when they are not defined, have the same definitions as those mentioned above.
  • Among the compounds of formula (I) which are subjects of the invention, a first group of compounds is constituted of the compounds for which:
      • A is a nitrogen atom,
      • X is a CH group.
  • Among the compounds of formula (I) which are subjects of the invention, a second group of compounds is constituted by the compounds for which:
      • R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from a halogen atom or a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy or halo(C1-C6)alkoxy group.
  • Among the compounds of formula (I) which are subjects of the invention, a third group of compounds is constituted of the compounds for which:
      • R1 is a phenyl, furan, thiophene or naphthalene group, optionally substituted with a halogen atom.
  • The combinations of the groups one to three as defined above are also part of the invention.
  • Among the compounds of formula (I) which are subjects of the invention, mention may in particular be made of the following compounds:
    • [5-(2-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
    • [5-(3-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
    • [5-(4-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
    • (5-furan-3-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
    • (5-thiophen-3-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
    • (5-naphthalen-2-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
    • (5-naphthalen-1-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone.
  • In the subsequent text, the term “protective group Pg” is intended to mean a group which makes it possible, on the one hand, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, on the other hand, to regenerate the intact reactive function at the end of synthesis. Examples of protective groups and also methods of protection and deprotection are given in “Protective Groups in Organic Synthesis”, Green et al., 2nd Edition (John Wiley & Sons, Inc., New York), 1991.
  • In the subsequent text, the term “leaving group” is intended to mean a group that can be readily cleaved from a molecule by breaking a heterolytic bond, with the departure of a pair of electrons. This group can thus be readily replaced with another group during a substitution reaction, for example. Such leaving groups are, for example, halogens or an activated hydroxyl group, such as a methanesulfonate, benzenesulfonate, p-toluenesulfonate, triflate, acetate, etc. Examples of leaving groups and also references for the preparation thereof are given in “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, 1985, p. 310-316.
  • In accordance with the invention, the compounds of general formula (I) can be prepared according to the process illustrated in scheme 1 which follows.
  • According to pathway A, in a first stage, the compounds of general formula (II), in which X is as defined above, are converted to compounds of general formula (III), in which X and R1 are as defined above. The conversion is carried out by means of a coupling reaction with a boronic acid or a boronate of respective general formula (IV) or (V), in which R1 is as defined above, and (OR″)2 is a pinacol group, catalyzed by a palladium complex.
  • In a second stage, the compounds of general formula (III), in which X and R1 are as defined above, are converted to compounds of general formula (VI), in which R1, R2, X and A are as defined above, by reaction with a carbamoyl chloride of general formula (VII). The reaction is carried out in a solvent such as N,N-dimethylformamide or N-methylpyrrolidone, in the presence of a base such as sodium hydride, potassium tert-butoxide or potassium tert-pentoxide.
  • In a third stage, the compounds of general formula (VI) are converted to compounds of general formula (VIII), in which R2, A, R1 and X are as defined above, by reduction of the nitro group to an amino group. The reaction can be carried out by various methods described in the literature or known to those skilled in the art, for instance hydrogenation in the presence of a catalyst based on palladium, platinum or nickel and variants thereof.
  • In the fourth stage, the compounds of general formula (VIII) are converted to compounds of general formula (I) by means of a diazotization/ring-closure reaction. The reaction can be carried out using a nitrite, for example sodium nitrite or potassium nitrite in an acidic medium or isoamyl nitrite or tert-butyl nitrite, in solvents such as water or tetrahydrofuran or a mixture thereof.
  • Figure US20110071162A1-20110324-C00003
  • Pathway B of scheme 1 illustrates an alternative method for preparing the compounds of formula (I).
  • In a first stage, the compounds of general formula (II) are converted to compounds of general formula (IX) by reaction with a carbamoyl chloride of general formula (VII) as defined above. In a second stage, the compounds of general formula (IX) are converted to compounds of general formula (VI) by reaction with a boronic acid or a boronate of general formula (IV) or (V), as defined above. The compounds of general formula (VI) are subsequently converted to compounds of general formula (VIII) and then to compounds of general formula (I) as specified above.
  • The compounds of general formulae (II), (IV) and (V) are commercially available. The carbamoyl chlorides of general formula (VII), if they are not commercially available, can be prepared by any method described in the literature or known to those skilled in the art, for example starting from the corresponding amines by reaction with phosgene, diphosgene or triphosgene.
  • The examples which follow illustrate the preparation of some compounds of the invention. These examples are not limiting, and merely illustrate the invention. The microanalyses, the IR and NMR spectra and/or the LC-MS confirm the structures and the purities of the compounds obtained. The melting points (Mp) are indicated in degrees Celsius.
    • EXAMPLE 1 Compound No. 3 of the Table [5-(4-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone 1.1. 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, (6-chloro-3-nitropyridin-2-yl)amide Pathway B:
  • Under an argon atmosphere, 0.55 g (13.83 mmol) of sodium hydride at 60% in oil is added portionwise to a solution of 1 g (5.76 mmol) of 2-amino-6-chloro-3-nitropyridine and 2 g (6.91 mmol) of 4-(3-trifluoromethylphenyl)-1-piperazinecarbonyl chloride (prepared from 1-(3-trifluoromethylphenyl)-piperazine and triphosgene) in 11 ml of dimethylformamide cooled with an ice bath. Stirring of the reaction medium is continued at the temperature of the ice bath for 15 minutes and then at ambient temperature for 2 hours. The mixture is cooled with an ice bath and 40 ml of a 1M aqueous solution of hydrochloric acid are added dropwise. 40 ml of ethyl acetate are added and the mixture is stirred vigorously for 15 minutes. The resulting mixture is adjusted to basic pH by adding a 1M aqueous solution of sodium hydroxide. The organic phase is separated by settling out and washed with 25 ml of water and 25 ml of a saturated aqueous solution of sodium chloride. The resulting product is dried over sodium sulfate and evaporated to dryness. The product is purified by silica gel chromatography, elution being carried out with an 80:20 then 60:40 mixture of cyclohexane and ethyl acetate. 1.54 g (yield: 62%) of product are obtained in the form of an orange gum.
  • 1H NMR (DMSO-d6, δ ppm): 8.65 (d, 1H), 7.40-7.75 (m+d, 4H), 7.35 (d, 1H), 3.90 (m, 4H), 3.50 (m, 4H).
    • 1.2. 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [6-(4-chlorophenyl)-3-nitropyridin-2-yl]amide Pathway B:
  • Under a nitrogen atmosphere, 0.64 g (1.50 mmol) of 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, (6-chloro-3-nitropyridin-2-yl)amide obtained in stage 1.1. (pathway B) is mixed with 0.33 g (2.1 mmol) of 4-chlorobenzeneboronic acid, 1.87 ml (3.75 mmol) of a 2M aqueous solution of sodium carbonate and 0.18 g (4.26 mmol) of lithium chloride in 100 ml of a pre-degassed mixture of ethanol/toluene/water (v/v: 1/1/0.4). 0.08 g (0.07 mmol) of tetrakis(triphenylphosphine)palladium(0) is added. The mixture is heated at 90° C. with stirring for 8 hours. The mixture is cooled to ambient temperature and then diluted with 50 ml of dichloromethane and 25 ml of water. The organic phase is separated by settling out and washed with 25 ml of water and 25 ml of a saturated solution of sodium chloride. The resulting product is dried over sodium sulfate and evaporated to dryness. The product is purified by silica gel chromatography, elution being carried out with an 80:20 then 60:40 mixture of cyclohexane and ethyl acetate. 0.6 g (yield: 79%) of product is obtained in the form of an oil.
  • 1H NMR (DMSO-d6, δ ppm): 8.55 (d, 1H), 8.30 (d, 2H), 8.00 (d, 1H), 7.80 (d, 2H), 7.80 (m, 1H), 7.60 (m, 1H), 7.40 (m, 2H), 7.20 (m, 1H), 3.8 (m, 4H), 3.50 (m, 4H).
  • Pathway A: alternatively, the 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [6-(4-chlorophenyl)-3-nitropyridin-2-yl]amide can be prepared as follows.
  • Under a nitrogen atmosphere, 1 g (5.76 mmol) of 2-amino-6-chloro-3-nitropyridine is mixed with 1.26 g (8.07 mmol) of 4-chlorobenzeneboronic acid, 7.2 ml (14.4 mmol) of a 2M aqueous solution of sodium carbonate and 0.7 g (16.36 mmol) of lithium chloride in 44 ml of a pre-degassed mixture of ethanol/toluene/water (v/v: 1/1/0.4). 0.34 g (0.29 mmol) of tetrakis(triphenylphosphine)palladium(0) is added. The mixture is heated at 90° C. with stirring for 18 hours. The resulting mixture is cooled to ambient temperature and then diluted with 50 ml of dichloromethane and 25 ml of water. The organic phase is separated by settling out and washed with 25 ml of water and 25 ml of a saturated solution of sodium chloride. The resulting product is dried over sodium sulfate and evaporated to dryness. The product is purified by silica gel chromatography, elution being carried out with a 50:50 then 80:20 mixture of dichloromethane and cyclohexane. 0.395 g (yield: 27%) of 6-(4-chlorophenyl)-3-nitropyridin-2-ylamine is obtained in the form of a white powder.
  • LC-MS (m/z): 250 (MH+)
  • 1H NMR (DMSO-d6, δ ppm): 8.45 (d, 1H), 8.15 (d, 1H), 7.95 (m, 2H), 7.60 (d, 1H), 7.30 (d, 1H), 7.20 (d, 1H).
  • This product is used as in stage 1.1 in order to obtain the 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [6-(4-chlorophenyl)-3-nitropyridin-2-yl]amide.
    • 1.3. 4-(3-(trifluoromethylphenyl)piperazine-1-carboxylic acid, [3-amino-6-(4-chlorophenyl)pyridin-2-yl]amide
  • In a hydrogenation flask, 0.72 g (1.44 mmol) of 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [6-(4-chlorophenyl)-3-nitropyridin-2-yl]amide, obtained in stage 1.2 (pathway A or B), is dissolved in a mixture of 250 ml of ethanol and 1.44 ml of a 1M aqueous solution of hydrochloric acid (1.44 mmol). 0.13 g of platinum (0.72 mmol) at 10% on charcoal is added. The mixture is stirred under a hydrogen atmosphere at a pressure of 40 Psi (2.5 bar) for 2 hours. 5 ml of a 5N solution of hydrochloric acid in isopropanol are added, the mixture is filtered through celite and washing is carried out with ethanol. The filtrate is evaporated so as to obtain 0.57 g (yield: 84%) of product in the form of a red powder.
  • LC-MS (m/z): 476 (MH+)
  • 1H NMR (DMSO-d6, δ ppm): 7.90 (d, 2H), 7.65 (d, 2H), 7.50 (m, 3H), 7.35 (m, 1H), 7.20 (m, 2H), 7.00 (m, 1H), 3.60 (m, 4H), 3.25 (m, 4H).
    • 1.4. [5-(4-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone
  • In a 100 ml three-necked flask, 0.55 g (1.17 mmol) of 4-(3-trifluoromethylphenyl)piperazine-1-carboxylic acid, [3-amino-6-(4-chlorophenyl)pyridin-2-yl]amide, obtained in stage 1.3., is dissolved in a mixture of 5 ml of water and 5 ml of 37% aqueous hydrochloric acid, cooled in an ice bath. Using a dropping funnel, 0.24 g (3.50 mmol) of sodium nitrite dissolved in 4 ml of water is added dropwise. The mixture is stirred for 2 hours at 0° C. It is left to stand for one hour in the ice bath and then the solid is filtered off. It is washed with 3×10 ml of water so as to obtain a beige solid. The latter is dried under vacuum in the presence of phosphorus pentoxide. The product is purified by silica gel chromatography, elution being carried out with an 80:20 then 60:40 mixture of cyclohexane and ethyl acetate. The oil obtained is crystallized from pentane so as to obtain 0.15 g (yield: 26%) of product in the form of a light yellow powder.
  • Melting point (° C.): 139-141° C.
  • LC-MS (m/z): 487 (MH+)
  • IR (KBr, cm−1): 1718, 1591
  • 1H NMR (DMSO-d6, δ ppm): 8.80 (d, 1H), 8.25 (dd, 3H), 7.60 (d, 2H), 7.45 (t, 1H), 7.25 (d, 1H), 7.20 (s, 1H), 7.10 (d, 1H), 3.30-4.00 (m, 8H).
  • Table 1 which follows illustrates the chemical structures and the physical properties of some examples of compounds according to the invention. In this table:
      • in the “salt” column, “-” represents a compound in the form of a free base, whereas “HCl” represents a compound in hydrochloride form;
      • Ph represents a phenyl group.
  • TABLE 1
    (I)
    Figure US20110071162A1-20110324-C00004
    Mp(° C.)
    No. R1 R2 X A Salt (Melting point)
    1 2-Cl—Ph 3-CF3—Ph CH N — 69-71
    2 3-Cl—Ph 3-CF3—Ph CH N — 102-104
    3 4-Cl—Ph 3-CF3—Ph CH N — 139-141
    4 furan-3-yl 3-CF3—Ph CH N — 68-70
    5 thien-2-yl 3-CF3—Ph CH N — 93-95
    6 naphthalen-1-yl 3-CF3—Ph CH N — 90-92
    7 naphthalen-1-yl 3-CF3—Ph CH N — 80-82
  • The compounds according to the invention surprisingly exhibit an inhibitory effect on the MGL (monoacyl glycerol lipase) enzyme. The MGL enzyme catalyzes the hydrolysis of endogenous derivatives of monoglyceride esters of various fatty acids (FEBS Letters 1998, 429, 152-156) and in particular the hydrolysis of 2-arachidonoylglycerol (2-AG) and of 1(3)-arachidonoylglycerol (1(3)-AG) (J. Biol. Chem. 1987, 272 (48), 27218-27223; Proc. Natl. Acad. Sci. USA 2002, 99 (16), 10819-10824; Biochem. Pharmacol. 2004, 67, 1381-1387; Mol. Pharmacol. 2004, 66 (5), 1260-1264). The 2-AG and 1(3)-AG derivatives in particular interact with cannabinoid receptors (J. Biol. Chem. 1999, 274 (5), 2794-2801; J. Biol. Chem. 2000, 275 (1), 605-612; British J. Pharmacol. 2001, 134, 664-672).
  • The compounds of the invention block this degradation pathway and increase the tissue levels of these derivatives, and in particular of 2-AG and/or of 1(3)-AG. In this respect, they can be used in the prevention and treatment of pathological conditions in which 2-AG and/or 1(3)-AG in particular, and/or any other substrate metabolized by the MGL enzyme, is (are) involved (Progress Lipid Research 2006, 45, 405-446).
  • The compounds according to the invention may also additionally have an inhibitory effect on the FAAH (Fatty Acid Amide Hydrolase) enzyme. The FAAH enzyme (Chemistry and Physics of Lipids (2000), 108, 107-121) catalyzes the hydrolysis of endogenous derivatives of amides and of esters of various fatty acids, such as N-arachidonoylethanolamine (anandamide), N-palmitoylethanolamine, N-oleoylethanolamine or oleamide. These derivatives exercise various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors.
  • The compounds of the invention block this degradation pathway and increase the tissue levels of these endogenous substances. In this respect, they can be used in the prevention and treatment of pathological conditions in which endogenous cannabinoids and/or any other substrate metabolized by the FAAH enzyme is (are) involved.
  • Tests comprised measuring the activity, in vitro, of the compounds of the invention on the MGL enzyme.
  • The inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis of 2-oleoyl glycerol ([3H] 2-OG) by MGL. The products of hydrolysis of [3H] 2-OG, labeled on the glycerol, are oleic acid and [3H] glycerol, and the source of MGL enzyme is a homogenate of mouse brain from which the cerebellum and the medulla oblongata have been removed. The mouse brains are removed, and stored at −80° C. until they are used, or homogenized immediately for twice 5 seconds using a Precellys apparatus at 5000 rpm (Bertin) in a 10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA buffer (pH 8) at 4° C. The concentration of the homogenates is then adjusted to 7.5 μg/μl.
  • The dilution series of the compounds is prepared from stock solutions at 20 mM in 100% DMSO. The first dilution of this series is prepared in 100% DMSO and then the second is prepared in the enzyme reaction buffer (50 mM phosphate, 0.1% BSA) leading to the preparation of a 10-times concentrated concentration range. The test compounds are preincubated at the selected concentration, for 20 minutes, with the mouse brain homogenate preparation. The final concentration of DMSO in the enzyme reaction does not exceed 0.1%.
  • Assaying of the MGL activity is carried out in a 96-well microplate in a final reaction volume of 100 μl. Briefly, 75 μg of proteins, preincubated with the test compounds, are diluted in 50 mM of phosphate buffer containing 0.1% BSA, and incubated, for 20 minutes at ambient temperature, in the presence of 50 μM of 2-OG containing an amount of [3H] 2-OG of 0.027 μCi/well (specific activity of 20 Ci/mmol). The reaction is stopped and the products formed are separated by adding and mixing 100 μl of chloroform/methanol (1/1). After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and a 30 μl aliquot of the aqueous phase containing the [3H] glycerol produced is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).
  • The inhibitory activity with respect to MGL is given by the concentration which inhibits 50% of the activity of MGL.
  • Under these conditions, the most active compounds of the invention exhibit an IC50 (concentration inhibiting 50% of the control enzyme activity of MGL) of between 0.001 and 0.1 μM.
  • For example, compounds Nos. 3 and 5 showed an IC50 of 0.002 and 0.007 μM, respectively.
  • Tests comprised measuring the activity, in vitro, of the compounds of the invention on the FAAH enzyme.
  • The inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis (ethanolamine [1-3H]) of anandamide by FAAH (Life Science (1995), 56, 1999-2005 and Journal of Pharmacology and Experimented Therapeutics (1997), 283, 729-734). The products of hydrolysis of [3H] anandamide, labeled on ethanolamine, are arachidonic acid and [3H]ethanolamine, and the source of FAAH enzyme is a homogenate of mouse brain from which the cerebellum and the medulla oblongata have been removed. The mouse brains are removed, and stored at −80° C. until they are used, or homogenized immediately for twice 5 seconds using a Precellys apparatus at 5000 rpm (Bertin) in a 10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA buffer (pH 8) at 4° C. The concentration of the homogenates is then adjusted to 20 μg/μl.
  • The dilution series of the compounds is prepared from stock solutions at 20 mM in 100% DMSO. The first dilution of this series is prepared in 100% DMSO, then the second is prepared in the enzyme reaction buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 8), 0.1% BSA) leading to the preparation of a 10-times concentrated concentration range. The test compounds are preincubated at the selected concentration for 20 minutes with the mouse brain homogenate preparation. The final concentration of DMSO in the enzyme reaction does not exceed 0.1%.
  • Assaying of the FAAH activity is carried out in a 96-well microplate in a final reaction volume of 70 μl. Briefly, 200 μg of mouse brain homogenate, preincubated with the test compounds, are diluted in 10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 8) containing 0.1% of BSA and incubated, for 20 minutes at ambient temperature, in the presence of 10 μM of anandamide containing an amount of [3H]-anandamide of 0.01 μCi/well (specific activity of 60 Ci/mmol). The reaction is stopped and the products formed are separated by adding and mixing 140 μl of chloroform/methanol (2/1). After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and a 30 μl aliquot of the aqueous phase containing the [3H]ethanolamine produced is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).
  • Under these conditions, the most active compounds of the invention exhibit an IC50 (concentration inhibiting 50% of the control enzyme activity of FAAH) of between 0.001 and 0.1 μM.
  • For example, compound No. 3 showed an IC50 of 0.002 μM.
  • It therefore appears that the compounds according to the invention have an inhibitory activity which is selective with respect to MGL or mixed with respect to MGL and FAAH.
  • The compounds according to the invention can therefore be used for the preparation of medicaments, in particular of medicaments which inhibit the MGL enzyme or the MGL and FAAH enzymes.
  • Thus, according to another of its aspects, a subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid, or else a hydrate or a solvate of the compound of formula (I).
  • These medicaments find use in therapeutics, in particular in the treatment and prevention of:
      • pain, in particular acute or chronic pain of neurogenic type: migraine, neuropathic pain including forms associated with the herpes virus and with diabetes;
      • acute or chronic pain associated with inflammatory diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome;
      • acute or chronic peripheral pain;
      • dizziness, vomiting, nausea, in particular subsequent to chemotherapy;
      • eating disorders, in particular anorexia and cachexia of various natures;
      • metabolic syndrome and manifestations thereof, including obesity;
      • dyslipidemia and manifestations thereof, including atherosclerosis and coronary diseases;
      • neurological and psychiatric pathological conditions: shaking, dyskinesia, dystonia, spasticity, obsessive-compulsive behavior, Tourette's syndrome, all forms of depression and anxiety of any nature or origin, mood disorders, psychoses;
      • acute and chronic neurodegenerative diseases: Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea, lesions associated with cerebral ischemia and with cranial and medullary trauma, amyotrophic lateral sclerosis;
      • epilepsy;
      • sleep disorders, including sleep apnea;
      • cardiovascular diseases, in particular hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischemia;
      • renal ischemia;
      • cancers: benign skin tumors, brain tumors and papillomas, prostate tumors, brain tumors (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependyomas, oligodendrogliomas, plexus tumors, neuroepitheliomas, epiphyseal tumors, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas);
      • immune system disorders, in particular autoimmune diseases: psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjögren's syndrome, ankylosing spondylarthritis, undifferentiated spondylarthritis, Behcet's disease, hemolytic autoimmune anemias, multiple sclerosis, amyotrophic lateral sclerosis, amyloses, transplant rejection, diseases affecting the plasmocytic line;
      • allergic diseases: immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis;
      • parasitic, viral or bacterial infectious diseases: AIDS, meningitis;
      • inflammatory diseases, in particular diseases of the joints: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome;
      • osteoporosis;
      • ocular conditions: ocular hypertension, glaucoma;
      • pulmonary conditions: respiratory tract diseases, bronchospasms, coughing, asthma, chronic bronchitis, chronic obstructive airway disease, emphysema;
      • gastrointestinal diseases: irritable bowel syndrome, intestinal inflammatory disorders, ulcers, diarrhea;
      • urinary incontinence and bladder inflammation.
  • According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active ingredient, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or a solvate of said compound, and also at least one pharmaceutically acceptable excipient.
  • Said excipients are selected, according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
  • In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or a possible salt, solvate or hydrate thereof, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or treatment of the disorders or diseases above.
  • Suitable unit administration forms comprise oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants. For topical application, the compounds according to the invention may be used in creams, gels, ointments or lotions.
  • By way of example, a unit administration form of a compound according to the invention in tablet form may comprise the following components:
  •
    Compound according to the invention 50.0 mg
    Mannitol 223.75 mg
    Sodium croscarmellose 6.0 mg
    Corn starch 15.0 mg
    Hydroxypropylmethylcellulose 2.25 mg
    Magnesium stearate 3.0 mg
  • According to another of its aspects, the present invention also relates to a method for treating the pathological conditions indicated above, which comprises the administration of an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt or hydrate or solvate thereof, to a patient.

Claims (18)

1. A method of treating a pathological condition in a patient in which endogenous 2-arachidonoylglycerol (2-AG) and endogenous 1(3)-arachidonoylglycerol or any other substrate metabolized by the monoacyl glycerol lipase (MGL) enzyme are involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
Figure US20110071162A1-20110324-C00005
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
2. The method according to claim 1, wherein for the compound of formula (I):
A is nitrogen; and
X is CH.
3. The method according to claim 1, wherein for the compound of formula (I):
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy.
4. The method according to claim 1, wherein for the compound of formula (I):
R1 is phenyl, furan, thiophene or naphthalene, optionally substituted with halogen.
5. The method according to claim 1, wherein the compound is selected from the group consisting of:
[5-(2-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
[5-(3-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
[5-(4-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
(5-furan-3-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
(5-thiophen-3-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
(5-naphthalen-2-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone; and
(5-naphthalen-1-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone.
6. A method of treating a pathological condition in a patient in which endogenous anandamide or any other substrate metabolized by the Fatty Acid Amide Hydrolase (FAAH) enzyme is involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
Figure US20110071162A1-20110324-C00006
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
7. The method according to claim 6, wherein for the compound of formula (I):
A is nitrogen; and
X is CH.
8. The method according to claim 6, wherein for the compound of formula (I):
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy.
9. The method according to claim 6, wherein for the compound of formula (I):
R1 is phenyl, furan, thiophene or naphthalene, optionally substituted with halogen.
10. The method according to claim 6, wherein the compound is selected from the group consisting of:
[5-(2-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
[5-(3-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
[5-(4-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
(5-furan-3-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
(5-thiophen-3-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone;
(5-naphthalen-2-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone; and
(5-naphthalen-1-yl[1,2,3]triazolo[4,5-b]pyridin-3-yl)[4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone.
11. A method of treating a disease selected from the group consisting of an inflammatory disease, dizziness, eating disorders, metabolic syndrome, dyslipidemia, epilepsy, a sleep disorder, osteoporosis, an ocular condition, a pulmonary condition, a gastrointestinal disease, urinary incontinence, and bladder inflammation, comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
Figure US20110071162A1-20110324-C00007
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 wherein the disease is an inflammatory disease.
13. The method according to claim 11 wherein the disease is dizziness.
14. The method according to claim 11 wherein the disease is selected from the group consisting of eating disorders, metabolic syndrome and dyslipidemia.
15. The method according to claim 11 wherein the disease is selected from the group consisting of epilepsy and a sleep disorder.
16. The method according to claim 11 wherein the disease is osteoporosis.
17. The method according to claim 11 wherein the disease is selected from the group consisting of an ocular condition and a pulmonary condition.
18. The method according to claim 11 wherein the disease is selected from the group consisting of a gastrointestinal disease, urinary incontinence and bladder inflammation.
US12/956,892 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof Abandoned US20110071162A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/956,892 US20110071162A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0702808 2007-04-18
FR0702808A FR2915198B1 (en) 2007-04-18 2007-04-18 TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
PCT/FR2008/000536 WO2008145843A1 (en) 2007-04-18 2008-04-16 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US12/577,777 US7863279B2 (en) 2007-04-18 2009-10-13 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US12/956,892 US20110071162A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/577,777 Continuation US7863279B2 (en) 2007-04-18 2009-10-13 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Publications (1)

Publication Number Publication Date
US20110071162A1 true US20110071162A1 (en) 2011-03-24

Family

ID=38776328

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/577,777 Expired - Fee Related US7863279B2 (en) 2007-04-18 2009-10-13 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US12/956,892 Abandoned US20110071162A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/577,777 Expired - Fee Related US7863279B2 (en) 2007-04-18 2009-10-13 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Country Status (17)

Country Link
US (2) US7863279B2 (en)
EP (1) EP2146992A1 (en)
JP (1) JP2010524908A (en)
KR (1) KR20090130061A (en)
CN (1) CN101663304A (en)
AR (1) AR066104A1 (en)
AU (1) AU2008257324A1 (en)
BR (1) BRPI0810412A2 (en)
CA (1) CA2683936A1 (en)
CL (1) CL2008001103A1 (en)
FR (1) FR2915198B1 (en)
IL (1) IL201471A0 (en)
MX (1) MX2009011213A (en)
RU (1) RU2009142434A (en)
TW (1) TW200901992A (en)
UY (1) UY31037A1 (en)
WO (1) WO2008145843A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130085130A1 (en) * 2011-09-30 2013-04-04 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2915198B1 (en) * 2007-04-18 2009-12-18 Sanofi Aventis TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
BRPI0923819B1 (en) * 2008-12-24 2021-11-09 Bial-Portela & Ca, S.A. FATTY ACID HYDROLASE AMIDE INHIBITOR COMPOUNDS, COMPOSITIONS AND USES
EP2421825B9 (en) 2009-04-22 2014-08-20 Janssen Pharmaceutica N.V. Azetidinyl diamides as monoacylglycerol lipase inhibitors
KR101820541B1 (en) 2009-09-09 2018-02-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 8-oxodihydropurine derivative
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
EA201690998A1 (en) 2010-05-17 2017-01-30 Инкозен Терапьютикс Пвт. Лтд. NEW CONNECTIONS OF 3,5-DESIGNED-3H-IMIDAZO [4,5-b] Pyridine and 3,5-DESIGNED-3H- [1,2,3] TRIAZOLO [4,5-b] Pyridine as modulators of protein kinase
EP2621918A1 (en) 2010-09-27 2013-08-07 Janssen Pharmaceutica, N.V. Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
KR20130142137A (en) * 2010-10-22 2013-12-27 얀센 파마슈티카 엔.브이. Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
EP2630139A1 (en) 2010-10-22 2013-08-28 Janssen Pharmaceutica, N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
JP2014076947A (en) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd 2-oxy substituted 8-oxodihydropurine derivative
WO2013049289A1 (en) * 2011-09-30 2013-04-04 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
EP2760861A1 (en) * 2011-09-30 2014-08-06 Janssen Pharmaceutica, N.V. Crystalline hydrochloride salt of (1- (4 -fluorophenyl) - 1h - indol - 5 - yl) - (3- (4- (thiazole - 2 - carbonyl) piperazin- 1 - yl) az etidin- 1 -yl) methanone and its use in the treatment of pain and metabolic disorders
EA026412B1 (en) * 2012-03-30 2017-04-28 Ризен Фармасьютикалз Са NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-b]PYRIDINE AND 3,5-DISUBSTITUED-3H-[1,2,3]TRIAZOLO[4,5-b]PYRIDINE COMPOUNDS AS MODULATORS OF C-met PROTEIN KINASES
RS62639B1 (en) * 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
CN107849017B (en) 2015-07-31 2021-03-30 辉瑞公司 1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAGL inhibitors
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
CA3045121A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
TWI770104B (en) 2017-01-11 2022-07-11 美商羅登醫療公司 Bicyclic inhibitors of histone deacetylase
KR20190104405A (en) 2017-01-20 2019-09-09 화이자 인코포레이티드 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivative as MAGL inhibitor
RU2726631C1 (en) 2017-01-23 2020-07-15 Пфайзер Инк. Heterocyclic spiro compounds as magl inhibitors
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
PL3664802T3 (en) 2017-08-07 2022-07-11 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. Compounds and their methods of use
KR102809796B1 (en) 2018-05-30 2025-05-20 프락시스 프리시젼 메디신즈, 인크. Ion channel regulator
EA202092908A1 (en) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. ION CHANNEL MODULATORS
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030011A1 (en) * 2005-10-19 2009-01-29 Sanofi-Aventis Triazolopyridine derivatives as inhibitors of lipases and phospholipases
US20100041651A1 (en) * 2007-04-18 2010-02-18 Sanofi-Aventis Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US7863279B2 (en) * 2007-04-18 2011-01-04 Sanofi-Aventis Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE10247680B4 (en) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh New bicyclic inhibitors of the hormone sensitive lipase
DE102004005172A1 (en) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazole derivatives as inhibitors of the hormone sensitive lipase
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030011A1 (en) * 2005-10-19 2009-01-29 Sanofi-Aventis Triazolopyridine derivatives as inhibitors of lipases and phospholipases
US20100041651A1 (en) * 2007-04-18 2010-02-18 Sanofi-Aventis Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US7863279B2 (en) * 2007-04-18 2011-01-04 Sanofi-Aventis Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
US20130085130A1 (en) * 2011-09-30 2013-04-04 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
US9375430B2 (en) * 2011-09-30 2016-06-28 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders

Also Published As

Publication number Publication date
AR066104A1 (en) 2009-07-22
FR2915198B1 (en) 2009-12-18
UY31037A1 (en) 2008-11-28
AU2008257324A1 (en) 2008-12-04
TW200901992A (en) 2009-01-16
BRPI0810412A2 (en) 2014-10-14
CL2008001103A1 (en) 2009-01-16
FR2915198A1 (en) 2008-10-24
WO2008145843A1 (en) 2008-12-04
IL201471A0 (en) 2010-05-31
KR20090130061A (en) 2009-12-17
CA2683936A1 (en) 2008-12-04
US20100041670A1 (en) 2010-02-18
US7863279B2 (en) 2011-01-04
MX2009011213A (en) 2009-11-02
EP2146992A1 (en) 2010-01-27
CN101663304A (en) 2010-03-03
RU2009142434A (en) 2011-05-27
JP2010524908A (en) 2010-07-22

Similar Documents

Publication Publication Date Title
US7863279B2 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US8080547B2 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US7868007B2 (en) Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
US7534800B2 (en) 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
US8889702B2 (en) Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
US20130211087A1 (en) 7-aza-spiro[3,5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof
NO20110598L (en) carbonate compounds
IL177326A (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
RS20050805A (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates preparation methods thereof and application of same in therapeutics
WO2005085252A1 (en) Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
KR20110034020A (en) Alkyl thiazole carbamate derivatives, their preparation, and their use as FAH enzyme inhibitors
US20080318949A1 (en) Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use
EP4011880A1 (en) Jak kinase inhibitor and use thereof
RS51246B (en) HETEROARIL-ALKYL CARBAMATE DERIVATIVES, THEIR PRODUCTION AND THEIR APPLICATION AS FAAH ENZYME INHIBITORS
HK1141802A (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
HK1142069A (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US9580422B2 (en) Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION